Pathology is a field that seems ripe for assistance from recent advances in artificial intelligence. Beck’s company is one of ...

The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

The S&P 500 added 1.1% on Wednesday, March 19, 2025, as the Fed held interest rates steady, reaffirming plans for future cuts ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) fell 3.4% following a recent Wall Street Journal report indicating that the ...